Daré Bioscience, Inc.
DAREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDaré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. At a $14.2M market cap, Daré Bioscience, Inc. ranks as a micro-cap company within healthcare. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
Market Cap
$14.2M
Beta
1.01
P/E (TTM)
—
P/E (Fwd)
-1.74
EPS (TTM)
$-0.66
EPS (Fwd)
$-0.41
ROE
—
ROA
-39.3%
Cash
$12.6M
Total Debt
$6.8M
Free CF
-$6.9M
52W Change
-66.6%
Annual Financials
Cash vs Debt
Where DARE stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DARE finished 58.66% below its 150-day moving average ($1.79) and 59.56% below its 200-day moving average ($1.83). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DARE overbought or oversold?
At the September 3, 2026 close, DARE's RSI(14) was 13.9, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $12.6M in cash and $6.8M in debt, DARE maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$6.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has pulled back from $10.0M (2022) to $1.0M (2025), a 90% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing DARE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.